Defining tumor antigens: mRNA, protein or cytotoxicity? [1]

Trends in Immunology

Volumn 23, Issue 5, 2002, Pages 236-237

  Lim, Seah H ^a   Periman, Phillip ^a   Klug, Panpit ^a   Weidanz, Jon ^a   Whitton, Vaughan ^a   Chiriva Internati, Maurizio ^a   Wang, Zhiqing ^a   Wright, Stephen ^a   Schultze, Joachim L ^b   Vonderheide, Robert H ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53; TUMOR ANTIGEN; TUMOR PROTEIN; TUMOR VACCINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL INTERACTION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE EXPRESSION; GENETIC CODE; HUMAN; IMMUNOLOGICAL TECHNIQUE; LETTER; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; TARGET CELL;

EID: 0036571084     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02196-8     Document Type: Letter

References (4)

1. J.L. Schultze R.H. Vonderheide From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens Trends Immunol. 22 2001 516 523
2. R. Offringa p53: a potential target antigen for immunotherapy of cancer Ann. New York Acad. Sci. 910 2000 223 233
3. M. Theobald Targeting p53 as a general tumor antigen Proc. Natl. Acad. Sci. U. S. A. 92 1995 11993 11997
4. P.A. Reay Determination of the relationship between T-cell responsiveness and the number of MHC–peptide complexes using specific monoclonal antibodies J. Immunol. 164 2000 5626 5634